Reynolds files lawsuit in California over tobacco products

May.15.2023
Reynolds files lawsuit in California over tobacco products
Reynolds Tobacco files lawsuit in California to defend its non-menthol tobacco products against flavor ban allegations.

On May 12th, Convenience Store News reported that Reynolds Tobacco filed a lawsuit against officials, including California Attorney General Robert Bonta, in response to several notices issued by Bonta alleging that Reynolds Tobacco and certain brands under the Empire Tobacco umbrella "presumptively" marketed flavored tobacco products.


Renault believes that the new product complies with California law.


Tobacco company Reynolds American Inc. has announced that it is taking action to maintain the availability of its legal "non-menthol" tobacco products in the California market. The company filed a lawsuit in California court seeking declaratory and injunctive relief, including the overturning of warning notifications from California authorities.


Renault Tobacco has expressed its support for its new products and believes that they comply with California's laws and can continue to be sold. Renault stated that it had followed all applicable pre-market regulatory requirements before launching these products for sale.


The company's statement stated:


The new Camel and Newport brand tobacco products do not have any discernible flavor or scent other than tobacco, and explicitly state that they are non-menthol on the market.


Renault Tobacco believes that the notification from the California Attorney General's office failed to acknowledge the fact that the newly launched product is prominently labeled as non-menthol and is being sold in the market.


California Attorney General Accuses Reno of Violating Flavoring Ban with New Product.


Previously, California's Attorney General, Xavier Becerra, issued warning letters to Reynolds and Imperial Tobacco stating that California law enforcement officials discovered through a review of cigarette packaging and promotional materials that several products were "presumed to be flavored products in violation of California's flavor ban.


The California Attorney General's office has identified seven products from R.J. Reynolds Tobacco, including Camel Crush Oasis Silver, Camel Crush Oasis Blue, Camel Crush Oasis Green, Camel Crisp, Newport EXP Non-Menthol Mix, Newport EXP Non-Menthol Max, and Newport Non-Menthol Green, as "flavored" tobacco products. Similarly, two products from Imperial Tobacco, Kool Non-Menthol and Kool Blue Non-Menthol, have been identified as "flavored" tobacco products as well.


These two companies are required to respond to these notices before June 23rd.


The Battle Against Flavored Tobacco in California.


On November 8th, 2022, California approved Proposition 31 with approximately 62.3% of voters in favor and 37.7% against. Proposition 31 upholds the state law banning the sale of flavored tobacco, including menthol.


The vote result was immediately met with opposition from tobacco companies, with companies such as Renault suing the California government in the US Supreme Court. However, on December 12th, the US Supreme Court rejected the plea of multiple tobacco companies to halt the implementation of the state's ban on the sale of flavored tobacco products.


According to Renault, the company has repeatedly urged law enforcement officials in California to take action against illegal and unregulated disposable electronic cigarettes that are being smuggled into the state from unknown sources through its ports.


Reference:


Reynolds has initiated legal action in California with the aim of safeguarding the legal sale and distribution of its tobacco products.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | Philip Morris Japan Launches Ginza-Exclusive IQOS ILUMA i PRIME, Limited to 1,814 Units at First Global Flagship
Product | Philip Morris Japan Launches Ginza-Exclusive IQOS ILUMA i PRIME, Limited to 1,814 Units at First Global Flagship
Philip Morris Japan (PMJ) launched the IQOS ILUMA i PRIME Ginza Limited Model Set in Tokyo on September 4, 2026, alongside the opening of IQOS Flagship Ginza, the brand’s first global flagship store. The Oasis Blue edition is limited to 1,814 individually numbered units, with the figure derived from the store’s address at Ginza 1-8-14. The set also includes two Yamanaka-nuri glasses and special packaging, priced at JPY 11,980 and sold exclusively at the Ginza flagship.
Sep.07
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
The Bombay High Court has ruled that airport duty-free shops are not exempt from India's domestic regulatory laws merely because they operate beyond the customs barrier, leaving in place a sales halt covering ZYN and FOX nicotine pouches at Mumbai's international airport. The court, however, did not determine that the products necessarily qualify as "drugs" under India's Drugs and Cosmetics Act. The retailers have four weeks to submit product information to the appropriate authorities, including CDSCO, which must complete its review within 30 days of receiving the submissions.
Sep.24
Trump Names Darrell Scott as CDC Tobacco Health Adviser, Citing Tobacco Risks and Harm-Reduction Solutions
Trump Names Darrell Scott as CDC Tobacco Health Adviser, Citing Tobacco Risks and Harm-Reduction Solutions
U.S. President Donald Trump has named Pastor Darrell Scott to serve as an adviser on tobacco health issues on the Centers for Disease Control and Prevention’s Advisory Committee to the Director. Trump said Scott would focus on the burden of tobacco-related disease and help examine ways to protect Americans from dangerous tobacco products while supporting solutions that reduce harm. Scott’s public career has largely centered on faith leadership, community advocacy and politics.
Sep.02
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Vaping brand PIXL has introduced the PIXL 5K reusable prefilled pod device in the UK, featuring a 2ml prefilled pod and a 4ml refill container with a combined e-liquid capacity of 6ml. The device uses 20mg/ml nicotine salt e-liquid and is advertised to deliver up to approximately 5,000 puffs. Available through UK retailers by August 2026, the PIXL 5K sits alongside the existing 12ml PIXL 8000. The UK's Vaping Products Duty took effect on October 1 at £0.22 per millilitre, producing theoretical duty amounts of £1.32 and £2.64 for the two products' respective full refill sets.
product
Oct.10
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
IQOS opened its first global flagship, IQOS Flagship Ginza, in Tokyo on September 4, 2026, replacing the former IQOS Store Ginza after nearly a decade of operation. The new location expands conventional product retail into member lounges, digital experiences, art installations and brand programming. IQOS also launched a Ginza-exclusive IQOS ILUMA i PRIME set limited to 1,814 individually numbered units, priced at JPY11,980, or about US$77. PMI Sales Strategy Consultant Yuji M. later said on LinkedIn that more than 500 people had lined up from the night before the opening.
Sep.07
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26